Clinical trial
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS…
NCT04032093 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT04032093 |
|---|---|
| Title | A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN |
| Official title | A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Tract Infection |
| Intervention type | Biological |
| Interventions | RSV vaccine, Placebo |
| Enrollment | 1,153 |
| Start date | Aug 7, 2019 |
| Primary completion | Sep 30, 2021 |
| Completion | Sep 30, 2021 |
| First posted | Jul 25, 2019 |
| Last update posted | Oct 18, 2022 |
| Countries | Argentina, Chile, New Zealand, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: